TY - JOUR
T1 - Frequency and burden of gastrointestinal symptoms in familial dysautonomia
AU - Ramprasad, Chethan
AU - Norcliffe-Kaufmann, Lucy
AU - Palma, Jose Alberto
AU - Levy, Joseph
AU - Zhang, Yian
AU - Spalink, Christy L.
AU - Khan, Abraham
AU - Smukalla, Scott
AU - Kaufmann, Horacio
AU - Chen, Lea Ann
N1 - Funding Information:
J.-A. Palma has received fees as consultant or advisory board member for Lundbeck, Takeda, Biogen, Dr. Reddy’s, and PTC; is the principal investigator in clinical studies sponsored by Theravance, Biohaven, and Biogen; receives research support from the National Institutes of Health, the Food and Drug Administration, the Familial Dysautonomia Foundation, Inc., the MSA Coalition, and the Michael J. Fox Foundation; and is managing editor of Clinical Autonomic Research. L. Norcliffe-Kaufmann has received fees as consultant or advisory board member for PTC and Theravance; receives research support from the National Institutes of Health, the Food and Drug Administration, the Familial Dysautonomia Foundation, and the Michael J. Fox Foundation. H. Kaufmann serves on a scientific advisory board for Lundbeck, Biogen, Theravance, Biohaven, and PTC; receives research support from the National Institutes of Health, the Food and Drug Administration, the Familial Dysautonomia Foundation, Inc., the MSA Coalition, and the Michael J. Fox Foundation; and serves as Editor-in-Chief of Clinical Autonomic Research. A. Khan is a consultant for Medtronic. All other authors have no conflicts of interest to report.
Funding Information:
This research was supported by National Institute of Neurological Disorders and Stroke (NINDS) grant U54NS065736 and the Familial Dysautonomia Foundation. Acknowledgements
Publisher Copyright:
© 2020, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2021/2
Y1 - 2021/2
N2 - Purpose: Familial dysautonomia (FD) is a rare hereditary sensory and autonomic neuropathy (HSAN-3) that is clinically characterized by impaired pain and temperature perception and abnormal autonomic function. Patients with FD have gastrointestinal dysmotility and report a range of gastrointestinal symptoms that have yet to be systematically evaluated. The aim of this study was to establish the frequency and severity of gastrointestinal symptoms in patients with FD. Methods: The validated National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) survey questionnaire, together with additional FD-specific questions, were distributed to 202 living patients with genetically confirmed FD who had been identified from the New York University FD Patient Registry or, when relevant, to their respective caretaker. As a comparison group, we used a general US adult population for whom PROMIS scores were available (N = 71,812). Results: Of the 202 questionnaires distributed, 77 (38%) were returned, of which 53% were completed by the patient. Median age of the respondents was 25 years, and 44% were male. Gastrostomy tube was the sole nutrition route for 25% of the patients, while 53% were reliant on the gastrostomy tube only for liquid intake. The prevalence of gastrointestinal symptoms was significantly higher in each of the eight domains of PROMIS in patients with FD than in the controls. Gastrointestinal symptoms as measured by raw scores on the PROMIS scale were significantly less severe in the FD patient group than in the control population in all domains with the exception of the abdominal pain domain. The surveys completed by caregivers reported the same burden of symptoms as those completed only by patients. Conclusion: Gastrointestinal symptoms affect nearly all patients with FD. Gastrointestinal symptoms are more prevalent in adult patients with FD than in the average US adult population but are less severe in the former.
AB - Purpose: Familial dysautonomia (FD) is a rare hereditary sensory and autonomic neuropathy (HSAN-3) that is clinically characterized by impaired pain and temperature perception and abnormal autonomic function. Patients with FD have gastrointestinal dysmotility and report a range of gastrointestinal symptoms that have yet to be systematically evaluated. The aim of this study was to establish the frequency and severity of gastrointestinal symptoms in patients with FD. Methods: The validated National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) survey questionnaire, together with additional FD-specific questions, were distributed to 202 living patients with genetically confirmed FD who had been identified from the New York University FD Patient Registry or, when relevant, to their respective caretaker. As a comparison group, we used a general US adult population for whom PROMIS scores were available (N = 71,812). Results: Of the 202 questionnaires distributed, 77 (38%) were returned, of which 53% were completed by the patient. Median age of the respondents was 25 years, and 44% were male. Gastrostomy tube was the sole nutrition route for 25% of the patients, while 53% were reliant on the gastrostomy tube only for liquid intake. The prevalence of gastrointestinal symptoms was significantly higher in each of the eight domains of PROMIS in patients with FD than in the controls. Gastrointestinal symptoms as measured by raw scores on the PROMIS scale were significantly less severe in the FD patient group than in the control population in all domains with the exception of the abdominal pain domain. The surveys completed by caregivers reported the same burden of symptoms as those completed only by patients. Conclusion: Gastrointestinal symptoms affect nearly all patients with FD. Gastrointestinal symptoms are more prevalent in adult patients with FD than in the average US adult population but are less severe in the former.
KW - Autonomic
KW - Motility
KW - Neurogastroenterology
KW - Patient reported outcomes
UR - http://www.scopus.com/inward/record.url?scp=85092112512&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092112512&partnerID=8YFLogxK
U2 - 10.1007/s10286-020-00735-9
DO - 10.1007/s10286-020-00735-9
M3 - Article
C2 - 33025279
AN - SCOPUS:85092112512
SN - 0959-9851
VL - 31
SP - 109
EP - 116
JO - Clinical Autonomic Research
JF - Clinical Autonomic Research
IS - 1
ER -